Table 1.
Descriptive summary statistics for the best cut-offs of LMR and NLR according to patient clinical characteristics, n=88
| Characteristics | All patients (n=88) |
LMR >3.20 (n=49) |
LMR ≤3.20 (n=39) |
NLR >2.18 (n=57) |
NLR ≤2.18 (n=31) |
| Age, years | |||||
| Median (range) | 54 (22–87) | 53 (22–87) | 54 (31–78) | 55 (31–87) | 52 (22–77) |
| >60, n (%) | 29 (33.0) | 16 (32.7) | 13 (33.3) | 24 (42.1) | 5 (16.1) |
| ≤60, n (%) | 59 (67.0) | 33 (67.4) | 26 (66.7) | 33 (57.9) | 26 (83.9) |
| Sex, n (%) | |||||
| Male | 47 (53.4) | 29 (59.2) | 18 (46.2) | 27 (47.4) | 20 (64.5) |
| Female | 41 (46.6) | 20 (40.8) | 21 (53.9) | 30 (52.6) | 11 (35.5) |
| FLIPI, n (%) | |||||
| Low risk (scores 0–1) | 16 (18.2) | 9 (18.4) | 7 (18.0) | 6 (10.5) | 10 (32.3) |
| Intermediate risk (score 2) | 19 (21.6) | 13 (26.5) | 6 (15.4) | 10 (17.5) | 9 (29.0) |
| High risk (scores 3–5) | 53 (60.2) | 27 (55.1) | 26 (66.7) | 41 (71.9) | 12 (38.7) |
| ANC (109/L), median (range) | 4.2 (1.9–10.7) | 3.7 (1.9–7.9) | 4.6 (2.1–10.7) | 4.6 (2.1–10.7) | 3.5 (1.9–7.9) |
| ALC (109/L), median (range) | 1.6 (0.6–11.3) | 1.9 (0.7–11.3) | 1.1 (0.6–3.1) | 1.2 (0.6–3.1) | 2.1 (1.4–11.3) |
| AMC (109/L), median (range) | 0.4 (0.1–1.2) | 0.4 (0.1–0.9) | 0.5 (0.2–1.2) | 0.4 (0.1–1.2) | 0.4 (0.2–1.1) |
| NLR, median (range) | 2.76 (0.59–9.91) | 2.15 (0.59–8.50) | 3.83 (1.81–9.91) | 3.50 (2.20–9.91) | 1.73 (0.59–2.18) |
| LMR, median (range) | 3.80 (0.55–22.60) | 5.00 (3.43–22.60) | 2.33 (0.55–3.20) | 3.00 (0.55–8.00) | 5.33 (2.82–22.60) |
| LDH >220 IU/L, n (%) | 70 (80.5) | 39 (81.3) | 31 (79.5) | 47 (82.5) | 23 (76.7) |
| Stage, n (%) | |||||
| I/II | 24 (27.3) | 14 (28.6) | 10 (25.6) | 11 (19.3) | 13 (41.9) |
| III/IV | 64 (72.7) | 35 (71.4) | 29 (74.4) | 46 (80.7) | 18 (58.1) |
| Hb <12 g/dL, n (%) | 23 (26.1) | 14 (28.6) | 9 (23.1) | 15 (26.3) | 8 (25.8) |
| Number of nodal sites >4, n (%) | 50 (56.8) | 24 (49.0) | 26 (66.7) | 37 (64.9) | 13 (41.9) |
| Use of rituximab, n (%) | 38 (43.2) | 19 (38.8) | 19 (48.7) | 27 (47.4) | 11 (35.5) |
| Treatment, n (%) | |||||
| Chemotherapy plus RT | 14 (15.9) | 9 (10.2) | 5 (5.7) | 8 (9.1) | 6 (6.8) |
| Chemotherapy alone | 54 (61.4) | 26 (29.5) | 28 (31.8) | 40 (45.5) | 14 (15.9) |
| RT alone | 14 (15.9) | 9 (10.2) | 5 (5.7) | 6 (6.8) | 8 (9.1) |
ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; FLIPI, Follicular Lymphoma International Prognostic Index; Hb, haemoglobin; LDH, lactate dehydrogenase; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; RT, radiotherapy.